# OnCo record dacomitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dacomitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dacomitinib" ;
  schema:name "Dacomitinib"@en ;
  schema:description "A second-generation EGFR pill that beat gefitinib on survival in EGFR-mutant lung cancer but was quickly overshadowed by osimertinib."@en ;
  schema:url <https://onco.cc/drugs/dacomitinib/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dacomitinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q17130597> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30608-3>, <https://doi.org/10.1200/JCO.2018.78.7994>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dacomitinib>, <https://www.nice.org.uk/guidance/ta595> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule pan-ErbB TKI (second generation, irreversible)" ;
  schema:alternateName "Vizimpro" ;
  onco:approval "US 2018: First-line metastatic NSCLC with EGFR exon 19 del or L858R", "EU 2019: Same", "England (NICE) 2019: Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer" ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct01774721/>, <https://onco.cc/trials/nct01360554/>, <https://onco.cc/trials/nct06486142/> .